(Q33648995)

English

Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

28 July 2017

Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure (English)

1 reference

Europe PubMed Central

28 July 2017

phase III clinical trial

0 references

0 references

gastrointestinal stromal tumor

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

9

object named as

Axel Le Cesne

0 references

12

object named as

Jean-Yves Blay

0 references

object named as

Grant A McArthur

13

0 references

Paolo Giovanni Casali

object named as

Paolo G Casali

19

0 references

Patrick Schöffski

3

object named as

Patrick Schöffski

1 reference

Europe PubMed Central

28 July 2017

5

object named as

Jaap Verweij

1 reference

Europe PubMed Central

28 July 2017

George D Demetri

1

object named as

George D Demetri

1 reference

Europe PubMed Central

28 July 2017

6

object named as

Serge Leyvraz

1 reference

Europe PubMed Central

28 July 2017

Antonio Lopez Pousa

8

object named as

Antonio Lopez Pousa

1 reference

Europe PubMed Central

28 July 2017

author name string

Christopher R Garrett

2

1 reference

Europe PubMed Central

28 July 2017

Manisha H Shah

4

1 reference

Europe PubMed Central

28 July 2017

Herbert I Hurwitz

7

1 reference

Europe PubMed Central

28 July 2017

David Goldstein

10

1 reference

Europe PubMed Central

28 July 2017

Luis Paz-Ares

11

1 reference

Europe PubMed Central

28 July 2017

Qiang Casey Xu

14

1 reference

Europe PubMed Central

28 July 2017

Xin Huang

15

1 reference

Europe PubMed Central

28 July 2017

Charles S Harmon

16

1 reference

Europe PubMed Central

28 July 2017

Vanessa Tassell

17

1 reference

Europe PubMed Central

28 July 2017

Darrel P Cohen

18

1 reference

Europe PubMed Central

28 July 2017

language of work or name

0 references

publication date

1 June 2012

1 reference

Europe PubMed Central

28 July 2017

Clinical Cancer Research

1 reference

Europe PubMed Central

28 July 2017

18

1 reference

Europe PubMed Central

28 July 2017

11

1 reference

Europe PubMed Central

28 July 2017

3170-3179

1 reference

Europe PubMed Central

28 July 2017

Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4030710

21 June 2018

Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4030710

21 June 2018

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4030710

21 June 2018

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4030710

21 June 2018

Molecular pathobiology of gastrointestinal stromal sarcomas.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4030710

21 June 2018

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4030710

21 June 2018

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4030710

21 June 2018

An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4030710

21 June 2018

SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4030710

21 June 2018

PDGFRA activating mutations in gastrointestinal stromal tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4030710

21 June 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4030710

21 June 2018

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4030710

21 June 2018

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4030710

30 October 2018

Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4030710

30 October 2018

SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4030710

30 October 2018

Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4030710

30 October 2018

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4030710

30 October 2018

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4030710

30 October 2018

Uses and limitations of randomization-based efficacy estimators

1 reference

https://pubmed.ncbi.nlm.nih.gov/22661587

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Angiogenesis inhibitors and hypertension: an emerging issue

1 reference

https://pubmed.ncbi.nlm.nih.gov/22661587

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Estimating treatment effects in randomized trials with treatment switching

1 reference

https://pubmed.ncbi.nlm.nih.gov/22661587

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/1078-0432.CCR-11-3005

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

28 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33648995&oldid=1971217905"